Scroll Top
Menu
Close
About us
Overview
Leadership Team
Board of Directors
Scientific Advisory Board
Partners
Careers
Science and Technology
Platform Technology
Science
Posters
Publications
Pipeline
Investors & Media
Overview
News & Events
Stock Information
Analyst Coverage
Investor Resources
SEC Filings
Governance Documents
Contact Us
Perspectives
Menu
Close
About us
Overview
Leadership Team
Board of Directors
Scientific Advisory Board
Partners
Careers
Science and Technology
Platform Technology
Science
Posters
Publications
Pipeline
Investors & Media
Overview
News & Events
Stock Information
Analyst Coverage
Investor Resources
SEC Filings
Governance Documents
Contact Us
Perspectives
Related Posts
Menu
Close
About us
Overview
Leadership Team
Board of Directors
Scientific Advisory Board
Partners
Careers
Science and Technology
Platform Technology
Science
Posters
Publications
Pipeline
Investors & Media
Overview
News & Events
Stock Information
Analyst Coverage
Investor Resources
SEC Filings
Governance Documents
Contact Us
Perspectives
Related Posts
Lysosomal storage disorder biotech Gain Therapeutics prices IPO at $11 midpoint
Nasdaq
Related Posts
Post navigation
Previous Post
Gain Therapeutics Announces Pricing of Initial Public Offering of Common Stock
Next Post
Gain Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Overallotment Option to Purchase Additional Shares
Latest Articles
Clear Filters
February 27, 2023
Gain Therapeutics Presents New Preclinical Data from its Gaucher Disease Program at the 19th Annual WORLDSymposium
Read More
June 25, 2024
Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
Read More
September 12, 2023
Gain Therapeutics Receives Approval to Commence Phase 1 Clinical Study of GT-02287 from the Human Research Ethics Committee (HREC) in Australia
Read More
Close
